No items found.
On January 27th, 2019, there was a gala ceremony called the “Crystal Wing Awards” which is held annually in theSlovak National Theatre. CEO of MultiplexDX, Dr. Pavol Cekan, was among the finalists for the award in a newly created category, “Start-ups and Innovations”. The “Crystal Wing Awards”recognize the most influential and successful people in their area of expertise and present publicly their inspiring stories. This year, the award granted to the laureates in 10 categories and a special award for lifetime achievement.
The nominee for the “Crystal Wing Award” in the category “Start-ups and Innovations”, Dr. Pavol Cekan comments:
“I am very honored to be among the best innovators and startupists in Slovakia. MultiplexDX achieved great success regarding investments and awards last year. I sacrificed my successful scientific career in the U.S. with the only goal to help oncological patients in Slovakia. I was nominated by common people; therefore, I really appreciate public interest in science and biotechnology startups, which will help to improve our health system and education.
The “Crystal Wing” jury recognizes outstanding public figures that significantly influence cultural, sport, economic, scientific and public life in Slovakia. Overall, there are 11 categories: theatre and audiovisual art, philanthropy, economy, music, medicine and science, journalism and literature, popular music, sport, fine arts, startups/innovations and the lifelong contribution award. The founder, Maria Vaskovicova, is proud that the award has flourished over 20 years of existence and continues to gain in popularity. Consequently, the“Crystal Wing Awards” is sometimes honored by analogy as the Slovak “NobelPrizes”.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.